Gastrointestinal Stromal Tumor (GIST) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Analysis of ctDNA Pinpoints Responders to Second-Line GIST Therapy
(MedPage Today) -- Circulating tumor DNA (ctDNA) analysis of KIT mutational status may be able to guide second-line treatment in patients with imatinib-resistant gastrointestinal stromal tumors (GIST), according to an exploratory analysis from... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 28, 2023 Category: Gastroenterology Source Type: news

Where Does Ripretinib Fit Into Treatment for GIST? Where Does Ripretinib Fit Into Treatment for GIST?
The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study Suggests Relationship Between Stromal Tumors and Mesothelioma
Early identification of peritoneal mesothelioma cancer – when it is most effectively treated – may become more common after a recent study revealed a potential link to gastrointestinal stromal tumors. A single-center retrospective review by the division of surgical oncology at University of California San Diego Moores Cancer Center identified a previously underrecognized, synchronous co-occurrence between the two rare diseases. Annals of Surgical Oncology published the case series in July, which found that one in every 17 patients undergoing resection for gastrointestinal stromal tumors, known as GISTs, also had ...
Source: Asbestos and Mesothelioma News - August 2, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Peritoneal Source Type: news

Is a Gastrointestinal Stromal Tumor a Soft Tissue Sarcoma?
Title: Is a Gastrointestinal Stromal Tumor a Soft Tissue Sarcoma?Category: Diseases and ConditionsCreated: 5/17/2022 12:00:00 AMLast Editorial Review: 5/17/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 17, 2022 Category: Cancer & Oncology Source Type: news

Is Gastrointestinal Stromal Tumor Cancerous?
Title: Is Gastrointestinal Stromal Tumor Cancerous?Category: Diseases and ConditionsCreated: 5/13/2022 12:00:00 AMLast Editorial Review: 5/13/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 13, 2022 Category: Cancer & Oncology Source Type: news

Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
CAMBRIDGE, Mass., Nov. 1, 2021 -- (Healthcare Sales & Marketing Network) --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercial... Biopharmaceuticals, Oncology, FDA Theseus Pharmaceuticals, targeted oncology, gastrointestinal stromal tumors (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2021 Category: Pharmaceuticals Source Type: news

Telehealth Took Off During the Pandemic. Now, Battles Over State Lines and Licensing Threaten Patients ’ Options
Televisits for medical care took off during the worst days of the pandemic, quickly becoming commonplace. Throughout, it’s probably seemed like it doesn’t matter what state the provider of these telehealth services is located. But that’s only because most states, along with the U.S. Centers for Medicare & Medicaid Services, temporarily waived rules requiring licensed clinicians to hold a valid license in the state where their patient is located. Now states are rolling back many of those pandemic workarounds—meaning the ability to conduct certain virtual appointments may be nearing an end. Johns ...
Source: TIME: Health - August 26, 2021 Category: Consumer Health News Authors: Julie Appleby / Kaiser Health News Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Founded by pioneers of targeted oncology, Theseus is developing best-in-class TKIs to overcome cancer resistance Presentation at AACR highlights THE-630, the Company's next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST) BO... Biopharmaceuticals, Oncology, Venture Capital Theseus Pharmaceuticals, targeted oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 13, 2021 Category: Pharmaceuticals Source Type: news

Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs Near-Infrared Imaging for Tumors Deep in Tissue, Such as GISTs
Near-infrared hyperspectral imaging combined with machine learning may hold promise for identifying deep-tissue gastrointestinal stromal tumors (GISTs).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chatter between cell populations drives progression of gastrointestinal tumors
(University of California - San Diego) Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2021 Category: International Medicine & Public Health Source Type: news

Deep Vision: Near-infrared imaging and machine learning can identify hidden tumors
(Tokyo University of Science) Gastrointestinal stromal tumors are tumors of the digestive tract that grow underneath the mucus layer covering our organs. Because they are deep inside the tissue, these " submucosal tumors " are difficult to detect and diagnose, even with a biopsy. Now, researchers from Japan have developed a novel minimally invasive and accurate method using infrared imaging and machine learning to distinguish between normal tissue and tumor areas. This technique has a strong potential for widespread clinical use. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Survival Rate for Gastrointestinal Stromal Tumors
What Is the Survival Rate for Gastrointestinal Stromal Tumors? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 27, 2021 Category: General Medicine Source Type: news

Genetic testing cost effective for newly diagnosed GIST
(University of California - San Diego) UC San Diego School of Medicine researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a rare type of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
CAMBRIDGE, Mass., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that ... Biopharmaceuticals, Regulatory Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2020 Category: Pharmaceuticals Source Type: news